NCT04923919 2023-07-13
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
Clinical Trials
10 trialsNCT05744440 2023-02-27
Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT
Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT05722171 2023-02-10
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05519384 2022-11-28
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT05432401 2022-06-27
TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05215015 2022-01-31
Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia
Wuxi People's Hospital
Phase EARLY_PHASE1 Unknown
NCT05016063 2021-08-23
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT03795779 2021-05-19
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT04209712 2020-07-29
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Phase EARLY_PHASE1 Unknown
NCT04156256 2019-11-12
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown